| Literature DB >> 35270507 |
Rudzani P Manafe1, Nolwazi L Bhembe-Magadaza1, Ezekiel Green1.
Abstract
Brucellosis is a widespread zoonotic illness, and it poses serious public health and economic risks. The purpose of this investigation is to look at the antimicrobial susceptibility of unpasteurized milk, blood, and lymph node specimens from cattle, goats, and sheep, as well as to identify virulence-associated genes. In this investigation, a total of 123 isolates were examined. The activity of 15 antimicrobials against Brucella pathogens were assessed using the Kirby-Bauer disk diffusion technique. Nine virulence factors were detected with polymerase chain reaction analysis. Five antibiotics were 100% effective against Brucella isolates. A high level of resistance (100%) was documented with streptomycin, penicillin, and seven more antibiotics. Doxycycline resistance was found in 12% of goat isolates, and tetracycline resistance was found in 21% and 44% of goat and sheep isolates, respectively. Multiple antibiotic resistance (MAR) index >0.2 was found in 38.2% (47/123) of Brucella isolates. VecC and BetB, two B. abortus genes, were confirmed to be comparable. The findings of this study suggests that Brucella spp. are reservoirs of antibiotic resistance in the Eastern Cape Province. As such, they represent a potential pool of antibiotic genes that might be transferred to other pathogens in the community, and thus continue to pose a healthcare hazard.Entities:
Keywords: Brucella; Brucella abortus; Brucella melitensis; brucellosis; multiple antibiotic resistance (MAR); prevalence; putative; virulence associated; zoonotic
Mesh:
Substances:
Year: 2022 PMID: 35270507 PMCID: PMC8909984 DOI: 10.3390/ijerph19052813
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
List of primers and PCR conditions used for the amplification of Brucella virulence-associated genes.
| Gene | Primer Sequence (5′-3′) | PCR Conditions | Amplicon Size (bp) | Reference |
|---|---|---|---|---|
| VirB5-F: ATTCTCAGCTTCGCATTC | Denaturation at 94 °C for 4 min, then 30 cycles of heat denaturation at 94 °C for 60 s, primer annealing at 56 °C for 45 s, and DNA extension at 72 °C for 1 min. To complete the synthesis of all strands, a last extension at 72 °C for 10 min is required. | 274 | [ | |
| BtpA-F: CTATCAGGCTAAGCAATTC | Denaturation at 94 °C for 4 min, then 30 cycles of heat denaturation at 94 °C for 60 s, primer annealing at 56 °C for 45 s, and DNA extension at 72 °C for 1 min. To complete the synthesis of all strands, a last extension at 72 °C for 10 min is required. | 458 | [ | |
| BtpB-F: TTAACCAGCACGAATACACG | Denaturation at 94 °C for 4 min, then 30 cycles of heat denaturation at 94 °C for 60 s, primer annealing at 61 °C for 45 s, and DNA extension at 72 °C for 1 min. To complete the synthesis of all strands, a last extension at 72 °C for 10 min is required. | 579 | [ | |
| VceC-F: CGCAAGCTGGTTCTGATC | Denaturation at 94 °C for 4 min, then 30 cycles of heat denaturation at 94 °C for 60 s, primer annealing at 61 °C for 45 s, and DNA extension at 72 °C for 1 min. To complete the synthesis of all strands, a last extension at 72 °C for 10 min is required. | 482 | [ | |
| BetB-F: GCTCGAAACGCTGGATAC | Denaturation at 94 °C for 4 min, then 30 cycles of heat denaturation at 94 °C for 60 s, primer annealing at 60 °C for 45 s, and DNA extension at 72 °C for 1 min. To complete the synthesis of all strands, a last extension at 72 °C for 10 min is required. | 393 | [ | |
|
| BPE275-F: TGTCGCGGTCTATGTCTATC | Denaturation at 94 °C for 4 min, then 30 cycles of heat denaturation at 94 °C for 60 s, primer annealing at 59 °C for 45 s, and DNA extension at 72 °C for 1 min. To complete the synthesis of all strands, a last extension at 72 °C for 10 min is required. | 466 | [ |
| VirB2-F: GCTGTCGCGGATTCTACC | Denaturation at 94 °C for 4 min, then 30 cycles of heat denaturation at 94 °C for 60 s, primer annealing at 60 °C for 45 s, and DNA extension at 72 °C for 1 min. To complete the synthesis of all strands, a last extension at 72 °C for 10 min is required. | 198 | [ | |
| BSPB-F: TATCCATGGTATATGCGCC | Denaturation at 94 °C for 4 min, then 30 cycles of heat denaturation at 94 °C for 60 s, primer annealing at 62 °C for 45 s, and DNA extension at 72 °C for 1 min. To complete the synthesis of all strands, a last extension at 72 °C for 10 min is required. | 336 | [ | |
| PrpA-F: AACCTCAATGGATCGACC | Denaturation at 94 °C for 4 min, then 30 cycles of heat denaturation at 94 °C for 60 s, primer annealing at 58 °C for 45 s, and DNA extension at 72 °C for 1 min. To complete the synthesis of all strands, a last extension at 72 °C for 10 min is required. | 672 | [ |
Antibiotic susceptibility testing of Brucella isolated from cattle, goats and sheep.
| Antibiotics | Cattle | Total (%) | Goats | Total (%) | Sheep | Total (%) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S | I | R | S | I | R | S | I | R | S | I | R | S | I | R | S | I | R | |
| Ciprofloxacin (10 µg) | 9 | 0 | 65 | 12 | 0 | 88 | 33 | 0 | 0 | 100 | 0 | 0 | 16 | 0 | 0 | 100 | 0 | 0 |
| Rifampicin (5 µg) | 0 | 0 | 74 | 0 | 0 | 100 | 0 | 0 | 33 | 0 | 0 | 100 | 0 | 0 | 16 | 0 | 0 | 100 |
| Amoxicillin (10 µg) | 0 | 0 | 74 | 0 | 0 | 100 | 0 | 0 | 33 | 0 | 0 | 100 | 0 | 0 | 16 | 0 | 0 | 100 |
| Doxycycline (30 µg) | 0 | 0 | 74 | 0 | 0 | 100 | 0 | 4 | 29 | 0 | 12 | 88 | 0 | 0 | 16 | 0 | 0 | 100 |
| Tetracycline (5 µg) | 0 | 0 | 74 | 0 | 0 | 100 | 0 | 7 | 26 | 0 | 21 | 79 | 0 | 7 | 9 | 0 | 44 | 56 |
| Trimethoprim–sulfamethoxazole (2.5 µg) | 0 | 0 | 74 | 0 | 0 | 100 | 33 | 0 | 0 | 100 | 0 | 0 | 16 | 0 | 0 | 100 | 0 | 0 |
| Ampicillin (10 µg) | 0 | 0 | 74 | 0 | 0 | 100 | 0 | 0 | 33 | 0 | 0 | 100 | 0 | 0 | 16 | 0 | 0 | 100 |
| Erythromycin (15 µg) | 0 | 0 | 74 | 0 | 0 | 100 | 0 | 0 | 33 | 0 | 0 | 100 | 0 | 0 | 16 | 0 | 0 | 100 |
| Ofloxacin (5 µg) | 74 | 0 | 0 | 100 | 0 | 0 | 33 | 0 | 0 | 100 | 0 | 0 | 16 | 0 | 0 | 100 | 0 | 0 |
| Cefixime (5 µg) | 61 | 0 | 13 | 82 | 0 | 18 | 33 | 0 | 0 | 100 | 0 | 0 | 16 | 0 | 0 | 100 | 0 | 0 |
| Moxifloxacin (5 µg) | 74 | 0 | 0 | 100 | 0 | 0 | 33 | 0 | 0 | 100 | 0 | 0 | 16 | 0 | 0 | 100 | 0 | 0 |
| Gentamicin (10 µg) | 74 | 0 | 0 | 100 | 0 | 0 | 33 | 0 | 0 | 100 | 0 | 0 | 16 | 0 | 0 | 100 | 0 | 0 |
| Penicillin G (10 units) | 0 | 0 | 74 | 0 | 0 | 100 | 0 | 0 | 33 | 0 | 0 | 100 | 0 | 0 | 16 | 0 | 0 | 100 |
| Levofloxacin (5 µg) | 74 | 0 | 0 | 100 | 0 | 0 | 33 | 0 | 0 | 0 | 0 | 100 | 16 | 0 | 0 | 100 | 0 | 0 |
| Cefoxitin (30 µg) | 0 | 0 | 74 | 0 | 0 | 100 | 33 | 0 | 0 | 100 | 0 | 0 | 16 | 0 | 0 | 100 | 0 | 0 |
Susceptibility (S), Intermediate (I), Resistance (R).
Antibiotypes and MARI of Brucella isolates.
| Antibiotic Code | Antibiotype | Number of Antibiotics | MARI |
|---|---|---|---|
| A1 | ER PGR RPR AR APR | 5 | 0.3 |
| A2 | ER PGR RPR AR DXTR APR | 6 | 0.5 |
| A3 | ER PGR RPR AR DXTR TR APR | 7 | 0.5 |
| A4 | ER PGR RPR AR DXTR TR SXTR APR FOXR | 9 | 0.6 |
| A5 | CIPR ER PGR RPR AR DXTR TR TSR APR | 9 | 0.6 |
| A6 | CIPR ER PGR RPR AR DXTR TR SXTR APR CFMR FOXR | 11 | 0.7 |
Amoxicillin (A), ciprofloxacin (CIP), doxycycline (DXT), penicillin G (PG), cefixime (CFM), trimethoprim/sulfamethoxazole (SXT), rifampicin (RIF), erythromycin (E), cefoxitin (Fox), tetracycline (T), ampicillin (AP).
Prevalence of genes linked to pathogenicity in the 120 Brucella isolates from livestock.
| Target Strains | Number (%) | Number of Putative Virulence Genes in Studied Strains | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
| 49 (40.8) | 3 (6.1) | 2 (4.1) | 1 (2) | 9 (18.4) | 17 (34.7) | 3 (6.1) | 0 | 14 (28.6) | 0 |
|
| 71 (59.2) | 10 (14.1) | 24 (33.8) | 5 (7) | 71 (100) | 71 (100) | 70 (98.6) | 65 (91.5) | 71 (100) | 4 (5.6) |
|
| 120 (100) | 13 (11) | 26 (22) | 6 (5) | 80 (67) | 88 (73) | 73 (61%) | 65 (54) | 85 (70.8) | 4 (3) |